Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C34H46O18 |
Molecular Weight | 742.7182 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 14 / 14 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CO[C@H](C3=CC(OC)=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(OC)=C3)[C@@]1([H])CO[C@H]2C5=CC(OC)=C(O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)C(OC)=C5
InChI
InChIKey=FFDULTAFAQRACT-JSGUJALWSA-N
InChI=1S/C34H46O18/c1-43-17-5-13(6-18(44-2)31(17)51-33-27(41)25(39)23(37)21(9-35)49-33)29-15-11-48-30(16(15)12-47-29)14-7-19(45-3)32(20(8-14)46-4)52-34-28(42)26(40)24(38)22(10-36)50-34/h5-8,15-16,21-30,33-42H,9-12H2,1-4H3/t15-,16+,21-,22-,23-,24-,25+,26+,27-,28-,29+,30-,33+,34+/m1/s1
Molecular Formula | C34H46O18 |
Molecular Weight | 742.7182 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 14 / 14 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Eleutheroside E is one of the active constituents of the Eleutherococcus senticosus (Rupr. & Maxim.) is also called Harms (ES), Acanthopanax senticosus, Siberian ginseng, or Gasiogapi in Korea. It is a diastereoisomer of Eleutheroside D. Eleutheroside E (EE) significantly decreased the inflammatory cell infiltration, pannus formation, cartilage damage, and bone erosion of collagen-induced arthritis mice, highlighting Eleutheroside E as a potential therapeutic agent for rheumatoid arthritis. Treatment of rat mesangial cells with Eleutheroside E markedly attenuated high glucose induced cells proliferation and in a dose-dependent manner. Intervention with EE also significantly blocked high glucose induced intracellular ROS production by decreasing NADPH oxidase activity. Intervention with EE also significantly blocked high glucose induced intracellular ROS production by decreasing NADPH oxidase activity. EE mediates the hyperglycemic effects of Eleutherococcus senticosus by regulating insulin signaling and glucose utilization. The beneficial effects of EE may provide an effective and powerful strategy to alleviate diabetes. Eleutheroside E exhibited weak inhibition against CYP2C9, CYP2E1 activity, and no effect on CYP2D6 and CYP3A4. The inhibition can result in the increase of the plasma concentration and toxicity of concomitant drugs, especially for those with narrow therapeutic windows such as warfarin, phenobarbital and phenytoin.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL5978 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24383621 |
188.4 µM [IC50] | ||
Target ID: CHEMBL4971 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24383621 |
261.8 µM [IC50] | ||
Target ID: GO:0038061 |
|||
Target ID: map00010 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23690865 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Immunopharmacological in vitro effects of Eleutherococcus senticosus extracts. | 2001 Jan |
|
A new lignan glycoside from Eleutherococcus senticosus. | 2001 Nov |
|
Quantitative determination of eleutheroside B and E from Acanthopanax species by high performance liquid chromatography. | 2001 Oct |
|
Application of bioreactor system for large-scale production of Eleutherococcus sessiliflorus somatic embryos in an air-lift bioreactor and production of eleutherosides. | 2005 Nov 4 |
|
Chemical structures and hepatoprotective effects of constituents from the leaves of Salacia chinensis. | 2011 |
|
Acanthopanax senticosus: review of botany, chemistry and pharmacology. | 2011 Feb |
|
Simultaneous quantification of polyherbal formulations containing Rhodiola rosea L. and Eleutherococcus senticosus Maxim. using rapid resolution liquid chromatography (RRLC). | 2011 Jul 15 |
|
The effect of Eleutheroside E on behavioral alterations in murine sleep deprivation stress model. | 2011 May 11 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21376030
Mice: 10 or 50 mg/kg body weight for 10 days, 1 h before each behavioral test
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23690865
To evaluate the effect of Eleutheroside E (EE) on impaired glucose uptake in an insulin-resistant state, we induced insulin resistance using TNF-𝛼 treatment in 3T3-L1 adipocytes and measured the effect of EE on TNF-𝛼-mediated suppression of glucose uptake. Treatment of 10 𝜇M EE for 24 h increased basal glucose uptake as well as improved TNF-𝛼-mediated suppression of glucose uptake. These data suggest that EE increases glucose uptake and could have a beneficial role
in insulin-resistant diabetes.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:12:01 GMT 2023
by
admin
on
Sat Dec 16 09:12:01 GMT 2023
|
Record UNII |
8JP2P44H3Z
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1234680
Created by
admin on Sat Dec 16 09:12:01 GMT 2023 , Edited by admin on Sat Dec 16 09:12:01 GMT 2023
|
PRIMARY | |||
|
39432-56-9
Created by
admin on Sat Dec 16 09:12:01 GMT 2023 , Edited by admin on Sat Dec 16 09:12:01 GMT 2023
|
PRIMARY | |||
|
DTXSID801316969
Created by
admin on Sat Dec 16 09:12:01 GMT 2023 , Edited by admin on Sat Dec 16 09:12:01 GMT 2023
|
PRIMARY | |||
|
8JP2P44H3Z
Created by
admin on Sat Dec 16 09:12:01 GMT 2023 , Edited by admin on Sat Dec 16 09:12:01 GMT 2023
|
PRIMARY | |||
|
71312557
Created by
admin on Sat Dec 16 09:12:01 GMT 2023 , Edited by admin on Sat Dec 16 09:12:01 GMT 2023
|
PRIMARY |